Headlines Expert Newsletters Covid-19 Specialties Trending Feeds Videos

Twitter Feed: VJHemOnc

Trending Latest

Mashup Score:4

VJHemOnc

The importance of patient-reported outcomes in CAR-T recipients - 22 hours

Mashup Score:4

Tune in to our latest podcast with leading experts who discuss the importance of patient-reported outcomes in CAR-T...

  • 1560522201027280896 Profile photo of Madelyn
    VJHemOnc

    📣 Tune in to our latest podcast, where leading experts discuss the importance of analyzing patient-reported outcomes in CAR-T recipients. 🎧: https://t.co/iavyo887ZV #HemOnc #ImmunoOnc #CARTcell #tcellrx - view on twitter

More coverage: #cartcell #hemonc #immunoonc #tcellrx
See more from

Mashup Score:4

VJHemOnc

Patient risk stratification in CLL and selection of treatment approaches - 6 days

Mashup Score:4

John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses patient risk stratification in chronic...

More coverage: #cllsm #eha2022 #hemonc #leusm
See more from

Mashup Score:3

VJHemOnc

The importance of circulating tumor DNA in patients with primary CNS lymphoma - 4 days

Mashup Score:3

Won Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, discusses the importance of plasma circulating...

More coverage: #eha2022 #hemonc #lymsm
See more from

Mashup Score:3

VJHemOnc

CAR-T therapy in myeloma and lymphoma - 1 week

Mashup Score:3

CAR-T therapy has revolutionized the treatment landscape of several hematological malignancies, and ongoing clinical trials continue to provide valuable...

  • 1558091955254460421 Profile photo of Madelyn
    VJHemOnc

    🚨 We've just posted a new podcast on #CART therapy in #Lymphoma & #MultipleMyeloma! 🎧 Listen to it here: 👉https://t.co/BKRVSW44By 👈 @VJHemOnc #iwCART22 #HemOnc #LYMsm #NonHodgkinLymphoma #DLBCL #FollicularLymphoma #MantleCellLymphoma #MMSM #Myeloma #ImmunoOnc #tcellrx - view on twitter

More coverage: #cart #dlbcl #follicularlymphoma #hemonc #immunoonc #iwcart22 #lymphoma #lymsm #mantlecelllymphoma #mmsm #multiplemyeloma #myeloma #nonhodgkinlymphoma #tcellrx
See more from

Mashup Score:3

VJHemOnc

Advances in allogeneic CAR-T therapy in lymphoma - 7 days

Mashup Score:3

Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses advances in allogeneic CAR-T therapy for the treatment of relapsed/refractory...

More coverage: #cartcell #eha2022 #hemonc #immunoonc #lymsm #tcellrx
See more from

Mashup Score:2

VJHemOnc

Genomic testing and clinical decision making in CLL - 5 days

Mashup Score:2

Learn more about the importance of genomic testing in CLL and how this influences clinical decision making with expert-led...

  • 1559087938297905154 Profile photo of Madelyn
    VJHemOnc

    Learn more about the importance of genomic testing in CLL w/ leading experts in our feature, covering: ➡️ the definition of high-risk disease ➡️ the role of genomic testing in prognosis ➡️ TP53 testing & more! 👉https://t.co/N7zOMFb3gZ👈 #CLLsm #LeuSM #HemOnc - view on twitter

More coverage: #cllsm #hemonc #leusm
See more from

Mashup Score:2

VJHemOnc

Emerging strategies to manage kidney disease in SCD patients - 11 hours

Mashup Score:2

In this video, Santosh Saraf, MD, University of Illinois Hospital, Chicago, IL, briefly discusses strategies to manage kidney disease...

More coverage: #eha2022 #hemonc #rarediseases #scd #sicklecell
See more from

Mashup Score:2

VJHemOnc

Unmet needs in AL amyloidosis: treatment options for R/R patients - 1 week

Mashup Score:2

Jahanzaib Khwaja, MD, FRCPath, University College London Hospitals NHS Foundation Trust, London, UK, comments on unmet needs in patients...

More coverage: #amyloidosis #hemonc #immunoonc #rarediseases
See more from

Mashup Score:2

VJHemOnc

The current standard of care for patients with lower-risk MDS - 2 days

Mashup Score:2

Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent’s Hospital Melbourne, Melbourne, Australia, briefly discusses the current standard of...

More coverage: #eha2022 #hemonc #mdssm
See more from

Mashup Score:1

VJHemOnc

Betibeglogene autotemcel receives FDA approval for patients with transfusion-dependent β-thalassemia - 15 hours

Mashup Score:1

On August 17 2022, the US Food and Drug Administration (FDA) approved the first cell-based gene therapy, betibeglogene autotemcel...

  • 1560628711673761795 Profile photo of Madelyn
    VJHemOnc

    📣 On August 17th, 2022, betibeglogene autotemcel received FDA approval for patients with transfusion-dependent β-thalassemia. Read more about it in our latest feature: 👉https://t.co/2SiaIzDijE👈 #HemOnc #RareDiseases #Thalassemia - view on twitter

More coverage: #hemonc #rarediseases #thalassemia
See more from
Load More